Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | ABCB1 | P08183 | 16/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | DRD4 | P21917 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23694447 | 1.00 | KDM4E (0.62) | KDM4EPOLBABCB1KMT2ALMNA | |
| SCHEMBL23694446 | 1.00 | KDM4E (0.62) | KDM4EPOLBABCB1KMT2ALMNA | |
| SCHEMBL23694639 | 0.99 | KDM4E (0.65) | KDM4EPOLBABCB1KMT2ALMNA | |
| SCHEMBL23694627 | 0.99 | KDM4E (0.65) | KDM4EPOLBABCB1KMT2ALMNA | |
| SCHEMBL23694628 | 0.99 | KDM4E (0.65) | KDM4EPOLBABCB1KMT2ALMNA | |
| SCHEMBL23694062 | 0.90 | POLB (0.56) | KDM4EPOLBABCB1LMNAMAPT | |
| SCHEMBL23694061 | 0.90 | POLB (0.56) | KDM4EPOLBABCB1LMNAMAPT | |
| SCHEMBL23694063 | 0.90 | POLB (0.56) | KDM4EPOLBABCB1LMNAMAPT | |
| SCHEMBL23694065 | 0.90 | MAPT (0.55) | KDM4EPOLBABCB1LMNAMAPT | |
| SCHEMBL23694634 | 0.90 | ABCB1 (0.64) | ABCB1KMT2ALMNAMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210228508-A1 | COMPOSITIONS AND METHODS THEREOF | Exciva GmbH | 2021-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210228508-A1 | COMPOSITIONS AND METHODS THEREOF | CYP21A2, CYP2C19, CYP2F1 | KDM4E 4018/4885POLB 2046/4885ABCB1 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.